Companies › Eli Lilly
91 active drug programs in 458 registered trials: 187 Phase 2, 118 Phase 3, 106 Phase 1, 47 Phase 4; Oncology, Metabolic and endocrine, Other, Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tirzepatide (LY3298176) Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist | GIPR, GLP1R | Phase 4 | Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis … | Nov 2026 |
| Lebrikizumab (LY3650150) Interleukin-13 inhibitor | IL13 | Phase 4 | Atopic Dermatitis; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Perennial Allergic Rhinitis (PAR) | Dec 2026 |
| Mirikizumab (LY3074828) Interleukin-23 inhibitor | IL12B, IL23A | Phase 4 | Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative … | Feb 2027 |
| Pirtobrutinib (LY3527727) Tyrosine-protein kinase BTK inhibitor | BTK | Phase 4 | Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Immune Thrombocytopenia (ITP) | Feb 2028 |
| Abemaciclib (LY2835219) Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 3 | Non Small Cell Lung Cancer; Breast Cancer; Breast Neoplasms; Prostatic Neoplasms … | Nov 2026 |
| Brenipatide (LY3537031) GLP-1 receptor agonist | GLP1R | Phase 3 | Depressive Disorder, Major; Alcohol Use Disorder; Smoking; Irritable Bowel Syndrome … | Nov 2026 |
| Galcanezumab (LY2951742) Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Episodic Migraine; Chronic Migraine | Nov 2026 |
| Retatrutide Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 3 | Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) … | Nov 2026 |
| Eloralintide (LY3841136) GLP-1/GCG dual receptor agonist | GLP1R, GCGR | Phase 3 | Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis … | Dec 2026 |
| Imlunestrant (LY3484356) Selective estrogen receptor degrader (SERD) | ESR1 | Phase 3 | Breast Neoplasms; Breast Cancer; Anatomic Stage I Breast Cancer AJCC v8 | Dec 2026 |
| Ramucirumab (LY3009806) Vascular endothelial growth factor receptor 2 inhibitor | KDR | Phase 3 | Metastatic Non-Small Cell Lung Cancer; Biliary Tract Cancer; Neoplasms; Recurrent Lung Non-Small Cell Carcinoma … | Dec 2026 |
| Orforglipron (LY3502970) GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Diabetes Mellitus, Type 2; Hypertension; Urinary Incontinence,Stress … | Feb 2027 |
| Selpercatinib Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer … | Feb 2027 |
| Olomorasib (LY3537982) KRAS G12C inhibitor | KRAS | Phase 3 | Carcinoma, Non-Small-Cell Lung; Healthy Volunteers | Apr 2027 |
| Donanemab (LY3002813) Amyloid-beta A4 protein disrupting agent | APP | Phase 3 | Alzheimer's Disease; Alzheimer Disease; Cognitive Dysfunction; Autosomal Dominant Alzheimers Disease | May 2027 |
| Pirtobrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; Lymphoma, Mantle-Cell; Richter Syndrome; Mantle Cell Lymphoma … | May 2027 |
| Vepugratinib (LY3866288) FGFR3 inhibitor | FGFR3 | Phase 3 | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Jun 2027 |
| Selpercatinib (LY3527723) Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor | RET, KIF5B, CCDC6 | Phase 3 | Medullary Thyroid Cancer | Nov 2027 |
| Dulaglutide (LY2189265) Glucagon-like peptide 1 receptor agonist | GLP1R | Phase 3 | Type 2 Diabetes; Myocardial Injury; Cystic Fibrosis; Diabetes Mellitus, Type 1 … | Dec 2027 |
| Baricitinib (LY3009104) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | JAK1, JAK2 | Phase 3 | Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis … | Mar 2028 |
| AAVAnc80-hOTOF Adeno-associated virus serotype delivering functional otoferlin gene | OTOF | Phase 3 | Sensorineural Hearing Loss, Bilateral | Oct 2028 |
| Sofetabart Mipitecan (Sofe-M, LY4170156) | – | Phase 3 | Ovarian Neoplasms | Nov 2028 |
| Ixekizumab (LY2439821) Interleukin 17A inhibitor | IL17A | Phase 3 | Juvenile Psoriatic Arthritis; Plaque Psoriasis; Psoriasis Vulgaris; Type1 Diabetes Mellitus | Jan 2029 |
| Lepodisiran Sodium Lipoprotein(a) synthesis inhibitor (antisense oligonucleotide) | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD); Atherosclerosis | Mar 2029 |
| Remternetug (LY3372993) LRRK2 inhibitor | LRRK2 | Phase 3 | Alzheimer's Disease; Alzheimers Disease | Apr 2029 |
| Tersolisib (LY4064809/STX-478) PIK3CA inhibitor | PIK3CA | Phase 3 | Breast Neoplasms | May 2029 |
| Muvalaplin (LY3473329) Lipoprotein(a) biosynthesis inhibitor | APOA | Phase 3 | Elevated Lp(a) | Mar 2031 |
| LY3938577 GLP-1 receptor agonist | GLP1R | Phase 2 | Diabetes Mellitus, Type 2 | Nov 2026 |
| LY4515100 | – | Phase 2 | Acute Pain; Healthy | Nov 2026 |
| LY2784544 JAK inhibitor | JAK | Phase 2 | Neoplasms, Hematologic | Dec 2026 |
| LY3537021 NK1 receptor antagonist | – | Phase 2 | Nausea | Dec 2026 |
| Merestinib (LY2801653) Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Biliary Tract Cancer | Dec 2026 |
| Bimagrumab (LY3985863) Activin receptor type-2B antagonist | ACVR2B | Phase 2 | Obesity | Jan 2027 |
| Macupatide (LY3532226) Amylin receptor agonist | CALCR | Phase 2 | Obesity; Overweight | Mar 2027 |
| Solbinsiran (LY3561774) Antisense oligonucleotide targeting APOC3 mRNA, reducing apoC-III levels and triglycerides | APOC3 | Phase 2 | Severe Hypertriglyceridemia | Mar 2027 |
| LY3016859 | – | Phase 2 | Osteoarthritis, Knee | Apr 2027 |
| LY3526318 | – | Phase 2 | Osteoarthritis, Knee | Apr 2027 |
| LY3556050 | – | Phase 2 | Osteoarthritis, Knee | Apr 2027 |
| LY3857210 | – | Phase 2 | Osteoarthritis, Knee | Apr 2027 |
| LY4065967 | – | Phase 2 | Osteoarthritis, Knee; Chronic Pain; Diabetic Peripheral Neuropathic Pain | Apr 2027 |
| Clazakizumab (LY5724886) Interleukin-6 inhibitor | IL6 | Phase 2 | Atherosclerosis | May 2027 |
| LY3457263 | – | Phase 2 | Type 2 Diabetes | May 2027 |
| LY4005130 | – | Phase 2 | Vitiligo; Alopecia Areata | May 2027 |
| LY4268989 | – | Phase 2 | Ulcerative Colitis; Ulcerative Colitis (UC); Healthy | May 2027 |
| LY4395089 Farnesoid X receptor (FXR) agonist | NR1H4 | Phase 2 | Colitis, Ulcerative; Crohn Disease | Jun 2027 |
| Eltrekibart OX40 agonist | OX40 | Phase 2 | Ulcerative Colitis | Jul 2027 |
| LY3305677 | – | Phase 2 | Obesity | Sep 2027 |
| LY3549492 | – | Phase 2 | Obesity | Sep 2027 |
| LOXO-783 PIK3CA inhibitor | PIK3CA | Phase 1 | Breast Cancer | Dec 2026 |
| LY4167586 unclear - GLP-1 receptor agonist (suspected based on indication and Eli Lilly pipeline) | – | Phase 1 | Overweight | Dec 2026 |
| Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| LY4355756 | – | Phase 1 | Healthy | Jan 2027 |
| LY3981314 | – | Phase 1 | Healthy | Feb 2027 |
| LY4057996 GLP-1 receptor agonist | – | Phase 1 | Diabetes Mellitus, Type 1 | Mar 2027 |
| LY4101174 | – | Phase 1 | Metastatic Solid Tumor | Mar 2027 |
| LY4152199 | – | Phase 1 | Lymphoma, Non-Hodgkin | Apr 2027 |
| LY3410738 Covalent isocitrate dehydrogenase (IDH) inhibitor | IDH1, IDH2 | Phase 1 | Acute Myeloid Leukemia (AML); Cholangiocarcinoma | May 2027 |
| LY4052031 | – | Phase 1 | Metastatic Solid Tumor | May 2027 |
| LY4006895 | – | Phase 1 | Alzheimer Disease | Jul 2027 |
| LY4088044 | – | Phase 1 | Healthy | Jul 2027 |
| LY4226695 | – | Phase 1 | Healthy | Jul 2027 |
| LY3200882 | – | Phase 1 | Solid Tumor | Aug 2027 |
| LY3295668 Erbumine | – | Phase 1 | Neuroblastoma | Aug 2027 |
| LY3300054 | – | Phase 1 | Solid Tumor | Aug 2027 |
| LY3439539 | – | Phase 1 | Alzheimer Disease | Aug 2027 |
| LY4256984 | – | Phase 1 | ALS (Amyotrophic Lateral Sclerosis); Amyotrophic Lateral Sclerosis | Aug 2027 |
| LY4302814 | – | Phase 1 | Healthy | Aug 2027 |
| LY5625575 | – | Phase 1 | Healthy Volunteers | Aug 2027 |
| LY4066708 | – | Phase 1 | Healthy | Sep 2027 |
| LY4329090 GLP-1 receptor agonist | – | Phase 1 | Obesity | Sep 2027 |
| [Ac-225]-PSMA-62 Actinium-225 labeled anti-PSMA targeted alpha particle therapy | PSMA | Phase 1 | Prostate Cancer | Sep 2027 |
| LY4050784 SMARCA4/BRG1 inhibitor | SMARCA4 | Phase 1 | Metastatic Solid Tumor | Oct 2027 |
| LY3971297 | – | Phase 1 | Heart Failure | Nov 2027 |
| [18F]LY4214835 Positron emission tomography (PET) imaging agent | – | Phase 1 | Neoplasms | Dec 2027 |
| LY4405094 Amyloid-targeting therapy | – | Phase 1 | Healthy Volunteers; Alzheimer Disease | Jan 2028 |
| LY3962673 KRAS G12D inhibitor | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Mar 2028 |
| LY4178256 | – | Phase 1 | Healthy Volunteers | Mar 2028 |
| LY4213663 | – | Phase 1 | Rheumatoid Arthritis (RA) | Mar 2028 |
| LY4298445 | – | Phase 1 | Healthy | Mar 2028 |
| LY3954068 LRRK2 inhibitor | – | Phase 1 | Alzheimer Disease | Jul 2028 |
| LY4337713 FAP-targeting antibody-drug conjugate | – | Phase 1 | Ovarian Neoplasms | Jul 2028 |
| LY4584180 | – | Phase 1 | Lymphoma, Non-Hodgkin's | Sep 2028 |
| LY4006896 | – | Phase 1 | Parkinson Disease | Oct 2028 |
| LY4174794 | – | Phase 1 | Obesity | Apr 2029 |
| AAVAnc80-antiVEGF AAV-mediated anti-VEGF gene therapy | VEGFA | Phase 1 | Vestibular Schwannoma | Aug 2029 |
| LY4066434 Pan-KRAS inhibitor | KRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2030 |
| LY4257496 GRPR-targeting therapeutic (mechanism to be determined in Phase 1) | GRPR | Phase 1 | Breast Neoplasms | Apr 2030 |
| LY4175408 unclear - mechanism not stated | – | Phase 1 | Carcinoma, Non-Small-Cell Lung | Jul 2030 |
| STX-478 mutant-selective PI3Kα inhibitor | PIK3CA | Phase 1 | Breast Cancer | Jul 2030 |
| LY3867070 | – | Phase 1 | Healthy | – |
| Tersolisib (LY4064809) PI3K inhibitor | PIK3CA | Phase 1 | Healthy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02747004 | Abemaciclib (LY2835219) | Phase 2 | Metastatic Breast Cancer | Oncology | Jun 2018 |
| NCT06936215 | Baricitinib (LY3009104) | Phase 3 | Diffuse Cutaneous Systemic Sclerosis | Immunology | May 2025 |
| NCT06768840 | Baricitinib (LY3009104) | Phase 2 | Vitiligo, Generalized | Immunology | Aug 2025 |
| NCT06280716 | Lebrikizumab (LY3650150) | Phase 3 | Atopic Dermatitis | Immunology | Sep 2025 |
| NCT03891784 | Abemaciclib (LY2835219) | Phase 2 | Advanced Digestive System Neuroendocrine Neoplasm | Oncology | Nov 2025 |
| NCT05894824 | Ramucirumab (LY3009806) | Phase 1 | Gastric Cancer | Oncology | Dec 2025 |
| NCT06037252 | Tirzepatide (LY3298176) | Phase 2 | Type 2 Diabetes | Metabolic and endocrine | Jan 2026 |
| NCT05955066 | Baricitinib (LY3009104) | Phase 4 | Rheumatoid Arthritis | Immunology | Feb 2026 |
| NCT07006792 | Lebrikizumab (LY3650150) | Phase 4 | Atopic Dermatitis | Immunology | May 2026 |
| NCT06630585 | Tirzepatide (LY3298176) | Phase 3 | Type 1 Diabetes (T1D) | Metabolic and endocrine | Jun 2026 |
| NCT06918405 | Tirzepatide (LY3298176) | Phase 3 | Obesity and Obesity-related Medical Conditions | Metabolic and endocrine | Jun 2026 |
| NCT06603571 | Eloralintide (LY3841136) | Phase 2 | Obesity | Metabolic and endocrine | Jul 2026 |
| NCT06603571 | Tirzepatide (LY3298176) | Phase 2 | Obesity | Metabolic and endocrine | Jul 2026 |
| NCT07423247 | Tirzepatide (LY3298176) | Phase 4 | Tirzepatide | Other | Jul 2026 |
| NCT06994338 | Tirzepatide (LY3298176) | Phase 2 | Alcohol Use Disorder | Metabolic and endocrine | Aug 2026 |
| NCT07662798 | Tersolisib (LY4064809) | Phase 1 | Healthy | Other | Sep 2026 |
| NCT07021547 | LY3867070 | Phase 1 | Healthy | Other | Sep 2026 |
| NCT07707375 | LY4268989 | Phase 1 | Healthy | Other | Oct 2026 |
| NCT07701083 | Eloralintide (LY3841136) | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT07426380 | Eloralintide (LY3841136) | Phase 1 | Kidney Disease | Genitourinary | Oct 2026 |
| NCT04088396 | Baricitinib (LY3009104) | Phase 3 | Systemic Juvenile Idiopathic Arthritis | Immunology | Oct 2026 |
| NCT07794592 | Olomorasib (LY3537982) | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT05677919 | Pirtobrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Nov 2026 |
| NCT05300932 | Baricitinib (LY3009104) | Phase 4 | Systemic Sclerosis | Immunology | Nov 2026 |
| NCT06662383 | Retatrutide | Phase 3 | Obesity | Metabolic and endocrine | Nov 2026 |
| NCT06297603 | Retatrutide | Phase 3 | Type 2 Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT07818967 | Abemaciclib (LY2835219) | Phase 1 | Healthy Volunteers | Other | Nov 2026 |
| NCT06962280 | Tirzepatide (LY3298176) | Phase 3 | Type 1 Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT06914895 | Tirzepatide (LY3298176) | Phase 3 | Type 1 Diabetes | Metabolic and endocrine | Nov 2026 |
| NCT07299084 | Tirzepatide (LY3298176) | Phase 1 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Nov 2026 |
| NCT07165002 | Brenipatide (LY3537031) | Phase 1 | Healthy | Gastroenterology | Nov 2026 |
| NCT06606106 | Brenipatide (LY3537031) | Phase 1 | Overweight | Metabolic and endocrine | Nov 2026 |
| NCT03432286 | Galcanezumab (LY2951742) | Phase 3 | Episodic Migraine | Neurology | Nov 2026 |
| NCT07511816 | LY4515100 | Phase 2 | Acute Pain | Other | Nov 2026 |
| NCT07215312 | LY3938577 | Phase 2 | Diabetes Mellitus, Type 2 | Metabolic and endocrine | Nov 2026 |
| NCT04660760 | Ramucirumab (LY3009806) | Phase 2 | Clinical Stage III Gastric Cancer AJCC v8 | Oncology | Nov 2026 |
| NCT04545710 | Abemaciclib (LY2835219) | Phase 2 | Lung Cancer | Oncology | Dec 2026 |
| NCT05305924 | Abemaciclib (LY2835219) | Phase 2 | ER-Positive Breast Cancer | Oncology | Dec 2026 |
| NCT04393285 | Abemaciclib (LY2835219) | Phase 2 | Endometrial Cancer | Oncology | Dec 2026 |
| NCT04268550 | Selpercatinib | Phase 2 | Recurrent Lung Non-Small Cell Carcinoma | Oncology | Dec 2026 |
| NCT05559359 | Lebrikizumab (LY3650150) | Phase 3 | Atopic Dermatitis | Immunology | Dec 2026 |
| NCT05509790 | Imlunestrant (LY3484356) | Phase 1 | Breast Neoplasms | Oncology | Dec 2026 |
| NCT07738614 | Eloralintide (LY3841136) | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT02152631 | Abemaciclib (LY2835219) | Phase 3 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT02246621 | Abemaciclib (LY2835219) | Phase 3 | Breast Cancer | Oncology | Dec 2026 |
| NCT03706365 | Abemaciclib (LY2835219) | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT02779751 | Abemaciclib (LY2835219) | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT02057133 | Abemaciclib (LY2835219) | Phase 1 | Breast Neoplasms | Oncology | Dec 2026 |
| NCT07803744 | Tirzepatide (LY3298176) | Phase 1 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Dec 2026 |
| NCT06901245 | Tirzepatide (LY3298176) | Phase 4 | Prader-Willi Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT07128082 | Tirzepatide (LY3298176) | Phase 2 | Long COVID | Infectious disease | Dec 2026 |
| NCT01594723 | LY2784544 | Phase 2 | Neoplasms, Hematologic | Oncology | Dec 2026 |
| NCT02411448 | Ramucirumab (LY3009806) | Phase 3 | Metastatic Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT02711553 | Ramucirumab (LY3009806) | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT03909334 | Ramucirumab (LY3009806) | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT03527108 | Ramucirumab (LY3009806) | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT02711553 | Merestinib (LY2801653) | Phase 2 | Biliary Tract Cancer | Oncology | Dec 2026 |
| NCT05307705 | LOXO-783 | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT02057133 | Samotolisib (LY3023414) | Phase 1 | Breast Neoplasms | Oncology | Dec 2026 |
| NCT07225556 | LY4167586 | Phase 1 | Overweight | Metabolic and endocrine | Dec 2026 |
The 60 nearest readouts of 458 trials; the rest in the app.
Cash of $4.9bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.